WO2011147254A1 - Phenylbutyryl curcumin derivatives and uses for preparing anti-tumor drugs thereof - Google Patents
Phenylbutyryl curcumin derivatives and uses for preparing anti-tumor drugs thereof Download PDFInfo
- Publication number
- WO2011147254A1 WO2011147254A1 PCT/CN2011/073844 CN2011073844W WO2011147254A1 WO 2011147254 A1 WO2011147254 A1 WO 2011147254A1 CN 2011073844 W CN2011073844 W CN 2011073844W WO 2011147254 A1 WO2011147254 A1 WO 2011147254A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- curcumin
- group
- pharmaceutically acceptable
- cancer
- Prior art date
Links
- -1 Phenylbutyryl curcumin derivatives Chemical class 0.000 title claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical class C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 73
- 229940109262 curcumin Drugs 0.000 claims abstract description 37
- 235000012754 curcumin Nutrition 0.000 claims abstract description 33
- 239000004148 curcumin Substances 0.000 claims abstract description 33
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 61
- 229940125904 compound 1 Drugs 0.000 claims description 57
- 229940125782 compound 2 Drugs 0.000 claims description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 13
- 201000007270 liver cancer Diseases 0.000 claims description 12
- 208000014018 liver neoplasm Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000012024 dehydrating agents Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000005690 diesters Chemical class 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003560 cancer drug Substances 0.000 claims 1
- 229950005499 carbon tetrachloride Drugs 0.000 claims 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 30
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 25
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 25
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 241000699660 Mus musculus Species 0.000 description 12
- 238000011789 NOD SCID mouse Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 238000011580 nude mouse model Methods 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 235000003392 Curcuma domestica Nutrition 0.000 description 6
- 244000008991 Curcuma longa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000003373 curcuma longa Nutrition 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 235000013976 turmeric Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- ZVHRTJHLSYKEAK-UHFFFAOYSA-N ethyl 2-[5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-2-oxo-3,4-dihydroquinolin-1-yl]acetate Chemical compound CCOC(=O)CN1C(=O)CCC2=C1C=CC=C2OC1=NC(=CC(CN)=C1)C(F)(F)F ZVHRTJHLSYKEAK-UHFFFAOYSA-N 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000013392 nude mouse xenograft model Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
Definitions
- the invention belongs to the field of pharmacy, and in particular relates to a phenylbutyryl curcumin derivative and a preparation method thereof, and the use thereof in preparing an antitumor drug.
- Curcumin (Cur) is an active ingredient extracted from the rhizome of the turmeric, turmeric, turmeric, and turmeric of the genus Zingiberaceae. It has anti-tumor, anti-inflammatory, anti-human immunodeficiency virus, anti-cholesterol, anti-oxidation and so on. A pharmacological effect has a good clinical application potential.
- Cur is unstable, rapid metabolism in the body, low bioavailability, and it is difficult to achieve an effective concentration in the body, which seriously restricts the development of curcumin into an effective anticancer drug.
- Curcumin derivatives synthesized through structural transformation, improve bioavailability, prolonged biological t 1/2 elimination half-life is important.
- One of the objects of the present invention is to provide 4-[bis(2-chloroethyl:)amino]phenylbutanoyl curcumin and 4,4'-[bis(2-chloroethyl:)amino]bisphenylbutanoyl turmeric And its pharmaceutically acceptable salt.
- a second object of the present invention is to provide 4-[bis(2-chloroethyl:)amino]phenylbutanoyl curcumin and 4,4'-[bis(2-chloroethyl:)amino]bisphenylbutanoyl turmeric And a method for preparing the pharmaceutically acceptable salt thereof.
- the pharmaceutically acceptable salts include alkali metal salts, alkaline earth metal salts, organic base-containing salts, and organic base-containing salts.
- the acceptable salts include calcium salts, magnesium salts, ammonium salts, triethylamine salts, and ethanolamine salts.
- the preparation method of the curcumin derivative and the salt of the present invention is specifically as follows: The curcumin is dissolved in the dried dichloromethane, and the catalytic amount of DMAP ( ⁇ , ⁇ -4-dimethylaminopyridine) is added. Then, 4-[bis(2-chloroethyl:)amino] phenylbutyric acid which has been dissolved in methylene chloride is added for esterification, and then the product is separated and purified by column chromatography.
- a dehydrating agent DCC (dicyclohexylcarbodiimide) or EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) may be added first.
- DCC diclohexylcarbodiimide
- EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
- the curcumin derivatives of the compound 1 and the compound 2 synthesized by the present invention are all obtained by nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR), ultraviolet spectroscopy (UV), and liquid chromatography-mass spectrometry (HPLC-Mass). After the identification of Compound 1 and Compound 2, a suitable pharmaceutically acceptable dosage form is prepared as needed.
- the present invention is a pharmaceutical composition or preparation comprising a medicament for protecting Compound 1 or Compound 2 or a pharmaceutically acceptable salt thereof, or a medicament containing Compound 1 or Compound 2 or a pharmaceutically acceptable salt thereof.
- the carrier is a conventional pharmaceutical carrier in the pharmaceutical field, such as a diluent, an excipient, a filler, a binder, a disintegrant, a surfactant, a lubricant, etc.;
- Various dosage forms for oral administration and other modes of administration such as oral liquids, suspensions, capsules, tablets, pills, granules, powder injections, etc.; prepared by conventional production methods in the pharmaceutical field, which are selected to contain weight percentages It is 0.1% to 99.5% active ingredient of Compound 1 or Compound 2.
- Pharmaceutical compositions which may also contain from 0.1% to 99.5% of Compound 1 or Compound 2; are those which can be practiced by one of ordinary skill in the art.
- the dosage of the present invention may be changed according to the route of administration, the age and weight of the patient, the type and severity of the disease to be treated, and the dose may be 0.001 - 10 g / k g body weight, which may be given one or more times. medicine.
- the third object of the present invention is to 4-[bis(2-chloroethyl:)amino]phenylbutanoyl curcumin and 4,4'-[bis(2-chloroethyl)amino]bisphenylbutanoyl curcumin, For the preparation of anti-tumor drugs.
- Curcumin derivatives can be used, but are not limited to, to prepare drugs for the treatment of leukemia, skin cancer, gastric cancer, colon cancer, liver cancer, breast cancer or prostate cancer.
- Leukemia is preferably human chronic myeloid leukemia.
- the compound 1 curcumin 4- [bis(2-chloroethyl)amino] phenylbutyrate of the present invention is significantly inhibited in various animal tumor cell transplantation models in vivo, especially
- the inhibitory effect on human chronic myeloid leukemia K562 cells in nude mice can be as high as 60%, and the weight of nude mice in the drug-administered group did not decrease significantly, and no animal died.
- FIG. 1 is a graph showing the inhibitory effect of intravenous administration of Compound 1 on mouse liver cancer H22 xenografts.
- Figure 2 is a graph showing the inhibitory effect of oral administration of compound 1 on liver cancer H22 xenografts in mice.
- Figure 3 is a graph showing the growth curve of compound 1 in human chronic myeloid leukemia K562 cells transplanted in nude mice.
- Figure 4 is a diagram showing the effect of Compound 1 on human chronic myeloid leukemia K562 cells transplanted in nude mice.
- Figure 5 and Figure 6 are the gross anatomy of mouse 1 in mouse model of human chronic myeloid leukemia and the mouse bone marrow bcr-abl gene. Expression map
- Figure 7 and Figure 8 are the peripheral blood images of NS group and compound 1 administered to human chronic myeloid leukemia model mice.
- Figure 9 is a graph showing the inhibitory effect of Compound 2 on mouse liver cancer H22 xenografts
- H22 mouse xenografts were established, and the physiological saline (control group) of the mice was intravenously administered, Compound 1 : 50, 70 mg/kg (administration group).
- the tumor inhibition rate is as high as 60%.
- H22 mouse xenografts were established and administered orally to mice with physiological saline (control group).
- Compound 1 50, 75, 100 mg/kg (administration group), curcumin 50 mg/kg (curcumin) Control group).
- the tumor inhibition rates of the drug-administered group were 41.21%, 52.93%, and 75.06%, respectively.
- the anti-tumor rate of the curcumin control group (equal to the compound lOOmg/kg) was only 16.58%, and the anti-tumor effect of the compound was significantly stronger than that of curcumin.
- a nude mouse xenograft model of human chronic myeloid leukemia K562 cells was established and administered orally to nude mice (control group), compound 1: 40, 60 mg/kg (administration group).
- control group nude mice
- compound 1 40, 60 mg/kg
- the length, width and height of the mouse tumor were measured with vernier calipers.
- Calculated tumor volume length> ⁇ width X height xl/2
- percentage of growth (%) (average tumor volume of the experimental group)
- the mean tumor volume of the control group was ⁇ 100%.
- the growth of tumors in the drug-administered group was significantly inhibited.
- a nude mouse xenograft model of ⁇ 562 cells was established and orally administered to nude mice (control group), compound 1: 40, 60 mg/kg (administration group).
- the tumor inhibition rates were 66.6% and 56.7%, respectively.
- a human chronic myeloid leukemia model was constructed using NOD-SCID mice.
- the control group was grossly dissected, and a large amount of bloody ascites was seen in the abdominal cavity, and solid tumors appeared.
- the characteristic gene bcr-abl of human chronic myeloid leukemia was detected by RT-PCR, indicating that human chronic myeloid leukemia cell K562 homing to the bone marrow of NOD-SCID mice.
- NOD-SCID mouse human chronic myeloid leukemia model was orally administered to normal saline (control group), compound 1: 60 mg/kg (administered group), peripheral blood group of the drug-administered group.
- the naive cells were also significantly less than the control group.
- the physiological saline (control group) of the mice was orally administered, Compound 2: 35, 50, 75, 115 mg/kg (administration group), curcumin 50 mg/kg (curcumin control group).
- the tumor inhibition rates of the drug-administered group were 27.43%, 32.25%, 62.60%, and 58.39%, respectively.
- Curcumin group (compound 100m g / kg equimolar) inhibition rate was 13.42%, visible inhibitory effect of Compound 2 significantly stronger than curcumin.
- EDCI 1 92g (10mmol) was dissolved in anhydrous dichloromethane 200ml, stirred in an ice bath and added with curcumin 7.36g (20mmol), DMAP 0. 244g (2mmol), then slowly added to dissolve 4- [Bis(2-chloroethyl)amino] phenylbutyric acid 3. 04 g (10 mmol) of dichloromethane (200 ml), and the reaction was further stirred at room temperature for 6 hours. After washing with distilled water, the organic phase was dried over anhydrous magnesium sulfate, and then filtered and evaporated to give a crude product.
- EDCI 1 92g (10mmol) was dissolved in 100ml of anhydrous dichloromethane, stirred in an ice bath and added with curcumin 1.84g (5mmol), DMAP 0. 122g (lmmol), then slowly added to dissolve 4- [Bis(2-chloroethyl)amino] phenylbutyric acid 3. 04 g (10 mmol) of dichloromethane (200 ml), and the reaction was further stirred at room temperature for 6 hours. After washing with distilled water, the organic phase was dried over anhydrous magnesium sulfate, and then filtered and evaporated to give a crude product.
- mice 8 ⁇ 12 weeks old Kunming healthy mice, female, weighing (20 ⁇ 2) g; mice were provided by Experimental Animal Center of Fujian Medical University (certificate No. SCXK ( ⁇ :) 200420002). Mouse liver cancer cell line H22.
- H22 tumor cells were passed for more than two generations. The number of cells was adjusted to 10 7 /ml, 0.2 mL/only inoculated into the right forelimb of mice, and 2 inoculated. After about two weeks, the tumor was stripped, homogenized, and inoculated again.
- a total of 3 groups The mice after 24 h inoculation of tumors were randomly divided into 3 groups: Group I was a saline control group, and Compound 1 was prepared by the method of the above examples. The same group II was compound 1 low. The dose group (Compound 1 50 mg/kg), Group III was Compound 1 high dose group (70 mg/kg), and the administration method was tail vein injection, 0.1 ml/10 g.
- mice A total of 5 groups: 24 hours after inoculation of tumors, the mice were randomly divided into 5 groups: group I was saline group (ie, tumor control group), group II was compound 1 low dose group (dose was 50 mg/kg) , III group compound 1 dose (a dose of 75mg / kg), IV group compound high dose groups (dose 100m g / k g), V group Cur group (at a dose of 50mg / kg, with a high dose Group IV equimolar), the method of administration is gavage,
- the tumor inhibition rate (%) the average tumor quality of the control group - the average tumor mass of the experimental group / the average tumor mass of the control group ⁇ %.
- Compound 1 has a significant inhibitory effect on the transplant rate of mouse liver cancer H22 (see Table 1, Figure 1 of the accompanying drawings).
- Table 1 Compound 1 intravenous administration to mouse liver cancer H22 xenograft inhibition agent number of rats tumor weight (g) tumor inhibition rate group other mg/kg > ⁇ day before / after (%)
- the antitumor effect of oral administration for 6 days was observed. It can be seen that the tumor inhibition rate increases with the increase of dose, showing a good dose-effect relationship.
- the anti-tumor rate of the drug-administered group (100m g /k g ) was significantly higher than that of the equimolar control drug curcumin (50 mg/kg), and no mice died in the large dose. Compound 1 was safer. (See Table 2 and Figure 2 of the drawing) Instruction manual
- K562 cells were passed for more than two generations, and the number of cells was adjusted to 5 ⁇ 10 7 /ml, 0.2 mL/only inoculated into the right forelimb of nude mice, and 30 cells were inoculated.
- mice After 6 days of inoculation of tumors, the mice were randomly divided into 3 groups according to the tumor size of the mice: Group I was the saline control group, and Group II was the compound 1 low dose group. 40 mg/kg), group III was compound 1 high dose group (60 mg/kg), and the administration method was intragastric administration, 0.1 ml/10 g.
- the tumor inhibition rate (%) (the average tumor mass of the control group - the average tumor mass of the experimental group) / the average tumor mass of the control group X 1 oo %.
- Fig. 3 of the accompanying drawings The dynamic changes of tumor growth in each group of tumor-bearing mice are shown in Fig. 3 of the accompanying drawings, and it can be seen that the tumor growth rate of the drug-administered group is significantly lower than that of the NS control group.
- mice Both female and male, 4 to 6 weeks old, weighing 18 to 22 g, provided by the Laboratory Animal Research Institute of the Chinese Academy of Medical Sciences, license number: SCXK (Beijing) 2005-0013.
- SCXK Beijing 2005-0013.
- NOD-SCID mice were housed in a SPF laboratory laminar box with a cover mouse (in accordance with SPF standards:). Standard pellet feed, drinking water, litter and all contact with the mouse are sterilized.
- NOD-SCID mice received whole body irradiation with 2.0 Gy X-rays, and K562 cells in logarithmic growth phase were used for transplantation the next day, and l xlO 7 cell/mouse was injected once in the tail vein.
- mice After transplanting K562 cells into NOD-SCID mice, they were randomly divided into normal saline control group and drug-treated group, with four groups in each group.
- the blank control group was given 0.2 ml/supply of normal saline, and the treatment group was administered with compound 1 60 mg/kg, and the administration was started two weeks after the transplantation, and the administration was continued for 5 days, and the treatment group was stopped for 5 days. Continuous medication for 8 days.
- the general condition, body weight and food intake of the mice were closely observed during the administration, and the toxicity of the drug and the tolerance of the animal to the drug were evaluated to adjust the administration schedule.
- the survival time of the mice in each experimental group was recorded for three months. The survival of K562 cells after transplantation for more than two months was long-term survival.
- mice in each experimental group were counted before the inoculation and 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks after the inoculation, and the total number of white blood cells was counted in the tail vein blood, and blood smears were prepared. , stained by Wright-Gimsa, sorted and counted under oil mirror.
- mice in the saline control group were 32.5 ⁇ 9.0 days after transplantation of human chronic myeloid leukemia cell K562.
- Peripheral blood leukocytes increased significantly in the three weeks after transplantation, which was 2-10 times before transplantation, and a large number of immature cells were seen in peripheral blood smears.
- the dead mice were grossly dissected, and a large amount of bloody ascites was seen in the abdominal cavity, and solid tumors appeared, and the splenomegaly was not obvious (see Figure 5 of the specification).
- the saline-controlled group of NOD-SCID mouse bone marrow cells detected the human bcr-abl gene by RT-PCR (see Figure 6 of the specification), indicating that human chronic myeloid leukemia cell K562 homing to the bone marrow of NOD-SCID mice.
- the human chronic granulocyte white blood model was successfully constructed.
- Compound 2 was prepared by the method of the above examples, and the test method of this example was the same as Compound 1.
- Compound 2 was formulated to the desired concentration prior to use.
- the mice with good tumor growth were sacrificed by cervical dislocation, the tumor pieces were removed under aseptic conditions, and the tumor tissues with good growth state were taken, and the single cell suspension was prepared by homogenization filtration, and the number of cells was adjusted to 1.
- OX IOVml each inoculation 0. 2ml was placed in the right axilla of the mouse to establish a H22 mouse xenograft model.
- mice were randomized by body weight, 9 mice per group, and the pre-dose weight was recorded.
- Tumor inhibition rate (%) [analytical tumor mass of the control group - mean tumor mass of the experimental group] / average tumor mass of the control group X 100%.
- the present invention can also be verified in the same manner as the above examples, including Compound 1 or Compound 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing Compound 1 or Compound 2 or a pharmaceutically acceptable salt form thereof having similar properties.
- the pharmaceutically acceptable salt include an alkali metal salt such as a sodium salt or a potassium salt, an alkaline earth metal salt such as a calcium salt or a magnesium salt, a salt containing an organic base such as an ammonium salt, or a salt of an organic base such as triethylamine.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1223251.8A GB2494595B (en) | 2010-05-26 | 2011-05-09 | Phenylbutyryl curcumin derivatives and use thereof in manufacturing medicaments for preventing tumors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010183509.6 | 2010-05-26 | ||
CN2010101835096A CN101830819B (en) | 2010-05-26 | 2010-05-26 | Phenylbutyryl curcumin derivate and application thereof in anti-tumor drug preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011147254A1 true WO2011147254A1 (en) | 2011-12-01 |
Family
ID=42715062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/073844 WO2011147254A1 (en) | 2010-05-26 | 2011-05-09 | Phenylbutyryl curcumin derivatives and uses for preparing anti-tumor drugs thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101830819B (en) |
GB (1) | GB2494595B (en) |
WO (1) | WO2011147254A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101830819B (en) * | 2010-05-26 | 2013-08-28 | 福建医科大学 | Phenylbutyryl curcumin derivate and application thereof in anti-tumor drug preparation |
CN102552224A (en) * | 2011-12-16 | 2012-07-11 | 西安交通大学 | Application of curcumin derivative C2 in anti-colon cancer medicaments |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031122A1 (en) * | 2002-10-01 | 2004-04-15 | Dr. André Rieks - Labor Für Enzymtechnologie Gmbh | Novel curcumin/tetrahydrocurcumin derivatives for using in cosmetics, pharmaceuticals and for nutrition |
WO2008045534A2 (en) * | 2006-10-12 | 2008-04-17 | Research Foundation Of The City University Of New York | Novel curcumin and tetrahydrocurcumin derivatives |
CN101669931A (en) * | 2008-09-08 | 2010-03-17 | 北京鼎国昌盛生物技术有限责任公司 | Application of long effective curcumin derivative in preparing anti-tumor disease drug |
CN101830819A (en) * | 2010-05-26 | 2010-09-15 | 福建医科大学 | Phenylbutyryl curcumin derivate and application thereof in anti-tumor drug preparation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
CN101003470B (en) * | 2007-01-22 | 2011-11-02 | 温州医学院生物与天然药物开发中心有限公司 | Analog of mono carbonyl structure of curcumin, and usage |
CN101255119B (en) * | 2008-01-07 | 2014-05-21 | 沈阳药科大学 | Novel tetrahydro curcumin derivatives and salt |
CN101434524B (en) * | 2008-06-05 | 2012-07-25 | 福建医科大学 | 4-(4-hydroxy-3-methoxybenzene methylene) curcumin, preparation thereof and use in preparing anti-cancer medicament |
CN101524546B (en) * | 2008-11-07 | 2012-06-06 | 浙江中医药大学 | Conjugate conjugated from polyethylene glycol and curcumin derivative |
-
2010
- 2010-05-26 CN CN2010101835096A patent/CN101830819B/en not_active Expired - Fee Related
-
2011
- 2011-05-09 WO PCT/CN2011/073844 patent/WO2011147254A1/en active Application Filing
- 2011-05-09 GB GB1223251.8A patent/GB2494595B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031122A1 (en) * | 2002-10-01 | 2004-04-15 | Dr. André Rieks - Labor Für Enzymtechnologie Gmbh | Novel curcumin/tetrahydrocurcumin derivatives for using in cosmetics, pharmaceuticals and for nutrition |
WO2008045534A2 (en) * | 2006-10-12 | 2008-04-17 | Research Foundation Of The City University Of New York | Novel curcumin and tetrahydrocurcumin derivatives |
CN101669931A (en) * | 2008-09-08 | 2010-03-17 | 北京鼎国昌盛生物技术有限责任公司 | Application of long effective curcumin derivative in preparing anti-tumor disease drug |
CN101830819A (en) * | 2010-05-26 | 2010-09-15 | 福建医科大学 | Phenylbutyryl curcumin derivate and application thereof in anti-tumor drug preparation |
Also Published As
Publication number | Publication date |
---|---|
GB201223251D0 (en) | 2013-02-06 |
CN101830819A (en) | 2010-09-15 |
GB2494595A (en) | 2013-03-13 |
GB2494595B (en) | 2018-03-21 |
CN101830819B (en) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112010839B (en) | Crystalline forms of a targeted silk/threonine kinase inhibitor | |
US20230102146A1 (en) | Multi-target tyrosine kinase inhibitor | |
JP7398156B2 (en) | A class of trialromatic compounds targeting the STAT3 bifunctional phosphorylation site and their applications | |
KR101975299B1 (en) | Compounds containing core structure of indole acetic acid and uses thereof | |
CN103965175B (en) | 4 (substitution phenylamino) quinazoline compounds, its preparation method and applications | |
WO2020029925A1 (en) | Multifunctional immunity-targeted micromolecule anti-cancer medicine bestazomib (bestazomib) and preparation method and application thereof | |
KR20200116132A (en) | Crystalline forms targeting CDK4/6 kinase inhibitors | |
WO2011147254A1 (en) | Phenylbutyryl curcumin derivatives and uses for preparing anti-tumor drugs thereof | |
CN101691384B (en) | Phosphate-containing toluylene compound, preparation method thereof and use thereof | |
CN104225611B (en) | The conjugate of Dasatinib and non-linear configurations polyethylene glycol | |
JP2013536204A (en) | Dicarboximide derivative of berbamine, its preparation method and use | |
JP5698741B2 (en) | 13a- (S) Deacidified Tyrophorinine Salt, Pharmaceutical Composition and Use | |
CN110938033A (en) | Selenocyanine compounds and uses thereof | |
CN109942665A (en) | Triptolide alcohol derivative and its preparation method and application | |
CN104744518B (en) | Ruthenium complex and its preparation method and application | |
CN104326937B (en) | Antitumoral compounds and medical usage thereof | |
US11833128B2 (en) | Ketone carbonyl-containing hydrophobic antitumor drug and conjugate thereof as well as nano preparation containing conjugate, preparation method therefor, and application thereof | |
CN109134470B (en) | Selenium-containing compound and application thereof | |
JP2004292426A (en) | Antimicrobial agent and anti-cancer agent | |
US20160102066A1 (en) | Benzothiazole derivative and anti-tumor use thereof | |
CN109553558B (en) | Selenium-containing compound and anti-tumor application thereof | |
CN112794853B (en) | Organic selenium compound and preparation method and application thereof | |
CN112794852B (en) | Selenium-containing organic compound and preparation method and application thereof | |
WO2017076307A1 (en) | Taccalonolide compound cyclodextrin inclusion compound, and preparation method and application thereof | |
KR20150030725A (en) | Anti lung cancer drug made of oleum cassiae and major constituent cinnamaldehyde thereof and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11786026 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 1223251 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20110509 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1223251.8 Country of ref document: GB |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11786026 Country of ref document: EP Kind code of ref document: A1 |